Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

被引：0
|
作者：
Mok, T. [1 ]
Wu, Y. -L. [2 ,3 ]
Sadowski, S. [4 ]
Zhang, J. [5 ]
Rangwala, R. [4 ]
de Lima Lopes, G. [6 ,7 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[4] Merck & Co Inc, Clin Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, BARDS, Kenilworth, NJ USA
[6] Oncoclin Brasil Grp, Oncol, Sao Paulo, Brazil
[7] Johns Hopkins Univ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
481TiP
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [21] Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study
    Wu, Yi-Long
    Zhang, Li
    Fan, Yun
    Zhou, JianYing
    Zhang, Li
    Zhou, Qing
    Li, Wei
    Hu, ChengPing
    Chen, GongYan
    Zhang, Xin
    Zhou, CaiCun
    Dang, Thao
    Sadowski, Sara
    Kush, Debra A.
    Zhou, Yu
    Li, Ben
    Mok, Tony
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (09) : 2313 - 2320
  • [22] Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001
    Soria, J. C.
    Flotten, O.
    Horn, L.
    Felip, E.
    Gandhi, L.
    Hui, R.
    Hellmann, M.
    Leighl, N.
    Zhang, J.
    Kondic, A.
    Rangwala, R.
    Lubiniecki, G. M.
    Garon, E. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S726 - S727
  • [23] KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
    de Castro, Gilberto
    Kudaba, Iveta
    Wu, Yi-Long
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Turna, Hande Z.
    Caglevic, Christian
    Zhang, Li
    Karaszewska, Boguslawa
    Laktionov, Konstantin K.
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Mukherjee, Rinee
    Lin, Jianxin
    Souza, Fabricio
    Mok, Tony S. K.
    Cho, Byoung Chul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A390 - A390
  • [24] Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
    Patnaik, Amita
    Socinski, Mark A.
    Gubens, Matthew A.
    Gandhi, Leena
    Stevenson, James
    Bachman, Robert D.
    Bourque, Jennifer
    Ge, Joy Yang
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
    Cho, Byoung Chul
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Kasahara, Kazuo
    Wu, Yi-Long
    Castro, Gilberto
    Turna, Hande Z.
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Pietanza, M. Catherine
    Piperdi, Bilal
    Mok, Tony S.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.
    Rizvi, Naiyer A.
    Garon, Edward B.
    Leighl, Natasha
    Hellmann, Matthew David
    Patnaik, Amita
    Gandhi, Leena
    Eder, Joseph Paul
    Rangwala, Reshma A.
    Lubiniecki, Gregory
    Zhang, Jin
    Emancipator, Kenneth
    Roach, Charlotte M.
    Rutledge, Ruth
    Hui, Rina
    Ahn, Myung-Ju
    Horn, Leora
    Felip, Enriqueta
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] MK-3475 (ANTI-PD-1 MONOCLONAL ANTIBODY) FOR NON-SMALL CELL LUNG CANCER (NSCLC): ANTITUMOR ACTIVITY AND ASSOCIATION WITH TUMOR PD-L1 EXPRESSION
    Gandhi, Leena
    Lubiniecki, Gregory
    Balmanoukian, Ani
    Hui, Rina
    Hamid, Omid
    Rizvi, Naiyer A.
    Leighl, Natasha
    Gubens, Matthew
    Goldman, Jonathan W.
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Lunceford, Jared K.
    Niewood, Michelle
    Gergich, Kevin
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S154 - S154
  • [28] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
    Gandhi, Leena
    Balmanoukian, Ani
    Hui, Rina
    Hamid, Omid
    Rizvi, Naiyer A.
    Leighl, Natasha
    Gubens, Matthew
    Goldman, Jonathan W.
    Lubiniecki, Gregory M.
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Lunceford, Jared K.
    Niewood, Michelle
    Gergich, Kevin
    Garon, Edward B.
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Vandormael, Kristel
    Riccio, Antonio
    Yang, Jing
    Pietanza, M. Catherine
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) : 537 - +
12345